Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
No abstract text is available yet for this article.
December 9, 2023: Targeted Oncology
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, Evaristo Maiello, Giuseppe Procopio, Vincenza Conteduca, Massimo Di Maio
No abstract text is available yet for this article.
December 9, 2023: Targeted Oncology
Serafina Martella, Marco Maria Aiello, Valentina Bertaglia, Riccardo Cau, Nerina Denaro, Andrea Cadoni, Silvia Novello, Mario Scartozzi, Giuseppe Novello, Hector Josè Soto Parra, Luca Saba, Cinzia Solinas, Michele Porcu
Malignant pleural mesothelioma (MPM) is a rare and challenging cancer associated with asbestos fiber exposure, which offers limited treatment options. Historically, platinum-based chemotherapy has been the primary approach, but recent developments have introduced immunotherapy as a promising alternative for the treatment of this disease. Nevertheless, the unique growth patterns and occasionally ambiguous progressive characteristics of MPM make the interpretation of radiological assessments complex. Immunotherapy further complicates matters by introducing unconventional treatment response patterns such as hyperprogression and pseudoprogression...
December 8, 2023: Targeted Oncology
Ming-Yu Lien, Tzer-Zen Hwang, Chih-Chun Wang, Ching-Yun Hsieh, Chuan-Chien Yang, Chien-Chung Wang, Ching-Feng Lien, Yu-Chen Shih, Shyh-An Yeh, Meng-Che Hsieh
BACKGROUND: Little is known regarding the prognostication of the Pan-Immune-Inflammation Value (PIV) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). OBJECTIVES: This study aimed to investigate the prognostic role of PIV in patients with R/M HNSCC receiving immune checkpoint inhibitors (ICI). PATIENTS AND METHODS: Patients who were diagnosed to have R/M HNSCC and treated with ICI were reviewed retrospectively...
December 2, 2023: Targeted Oncology
Simon Fung, Yahiya Y Syed
No abstract text is available yet for this article.
November 29, 2023: Targeted Oncology
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, Evaristo Maiello, Giuseppe Procopio, Vincenza Conteduca, Massimo Di Maio
BACKGROUND: PARP inhibitors (PARPis) are effective treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) as single agents or in combination with androgen receptor-targeted agents (ARTA). However, a clinically relevant adverse effect of these agents is hematological toxicity, a typical class adverse event (AE), which can lead to treatment modifications and discontinuations. OBJECTIVE: We aimed to analyze the risk of hematological AEs, including anemia, neutropenia, and thrombocytopenia secondary to PARPi treatments in mCRPC...
November 22, 2023: Targeted Oncology
Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, Hélène Doubre, Chantal Decroisette, Pierre Demontrond, Gwenaelle Le Garff, Lionel Falchero, Eric Huchot, Sabine Vieillot, Romain Corre, Laure Kazulinski, Acya Bizieux, Laurence Bigay-Gamé, Hugues Morel, Olivier Molinier, Christos Chouaïd, Florian Guisier
BACKGROUND: Although ALK-translocated (ALK+) advanced non-small cell lung cancers (aNSCLCs) are currently treated with second- or third-generation ALK inhibitors (ALK-TKIs), some patients respond durably to the first-generation ALK-TKI crizotinib. OBJECTIVE: This study aimed to describe the clinical characteristics of these long-term responders. PATIENTS AND METHODS: This national, multicenter, retrospective, non-interventional study included patients with ALK+ aNSCLCs and long-term responses to first (L1)- or subsequent (≥ L2)-line crizotinib, defined, respectively, as treatments lasting > 18 and > 10 months...
November 15, 2023: Targeted Oncology
Simon Fung, Yahiya Y Syed
Durvalumab (Imfinzi® ), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer. In the pivotal phase 3 TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin significantly prolonged overall survival and progression-free survival compared with placebo plus gemcitabine and cisplatin in adults with advanced biliary tract cancer...
November 9, 2023: Targeted Oncology
(no author information available yet)
No abstract text is available yet for this article.
November 7, 2023: Targeted Oncology
Lauren C Bylsma, Xerxes Pundole, Chia-Hsin Ju, Naushin Hooda, Naimisha Movva, Ehab Elkhouly, Gwyn Bebb, Jon Fryzek, Pablo Martinez, Akhila Balasubramanian, Anne-Marie C Dingemans
BACKGROUND: Delta-like ligand 3 (DLL3), a member of the Notch pathway, has been identified as a potential therapeutic target as it is highly expressed in small cell lung cancer (SCLC), a subtype accounting for 15% of lung cancer cases. OBJECTIVE: A systematic literature review (SLR) was conducted to understand the prevalence and prognostic impact of DLL3 expression on survival of patients with SCLC and treatment response. PATIENTS AND METHODS: Systematic literature searches were conducted across multiple databases to capture studies of any SCLC population that evaluated DLL3 expression...
November 6, 2023: Targeted Oncology
Marine Marchal, Vincent Leroy, Hélène Behal, Eric Dansin, Nicolas Paris, Soraya Bordier, Sarah Humez, Fabienne Escande, Clément Gauvain, Alexis B Cortot
BACKGROUND: Chemo-immunotherapy (CIT) is the standard of care for advanced non-small cell lung cancer (NSCLC), but the impact of routinely available histo-molecular biomarkers on its efficacy has not yet been fully assessed. OBJECTIVE: The purpose of this multicenter study was to evaluate the clinical activity of CIT according to oncogenic drivers, STK11 and TP53 mutations, and MET overexpression. PATIENTS AND METHODS: Patients receiving CIT for advanced NSCLC with available comprehensive molecular profile were included...
November 3, 2023: Targeted Oncology
Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Naoya Nishioka, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients with non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death-ligand 1 (PD-L1). However, appropriate treatment for patients showing high PD-L1 expression and poor performance status (PS) is not well defined. OBJECTIVE: The aim of this study was to identify a treatment option that is better for these patients in a real-world setting...
October 30, 2023: Targeted Oncology
Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
No abstract text is available yet for this article.
October 27, 2023: Targeted Oncology
Albiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, Myung-Ju Ahn, Pamela Munster, George Blumenschein, Benjamin Solomon, Darren Wan-Teck Lim, Ruey-Long Hong, David Pfister, Nabil F Saba, Se-Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean-Pierre Delord
BACKGROUND: Alpelisib in combination with cetuximab showed synergistic anti-tumour activity in head and neck squamous cell carcinoma (HNSCC) models. OBJECTIVES: The recommended phase 2 dose (RP2D) was determined in a phase 1b dose-escalation study. Phase 2 evaluated anti-tumour activity with a randomised part in cetuximab-naïve patients and a non-randomised part in cetuximab-resistant patients. PATIENTS AND METHODS:  Alpelisib was administered in 28 d cycles as whole tablets, suspension from crushed tablets or suspension from dispersible tablets in patients with platinum-resistant, recurrent/metastatic HNSCC...
October 25, 2023: Targeted Oncology
Alessandro Ottaiano, Francesco Sabbatino, Francesco Perri, Marco Cascella, Mariachiara Santorsola, Guglielmo Nasti
No abstract text is available yet for this article.
October 21, 2023: Targeted Oncology
Ning Wang, Zhenxian Mo, Lu Pan, Minhua Zhou, Xiaolan Ye, Xinjian Liu, Xiong Cai, Changgeng Qian, Feili Chen, Yan Xiong, Fushun Fan, Wenyu Li
BACKGROUND: The efficacy of systemic treatment for primary central nervous system lymphoma (PCNSL) is limited because of the blood-brain barrier (BBB) and the ineffectiveness of chemotherapy. The dual PI3K/HDAC inhibitor BEBT-908 has exhibited favorable in vivo distribution and activity in various cancers. OBJECTIVES: The aims of this study were to assess the efficacy of BEBT-908 in brain orthotopic mouse models of hematological malignancies, to investigate its pharmacologic properties, and to elucidate the underlying mechanism of action...
October 19, 2023: Targeted Oncology
James E Frampton
Ivosidenib (Tibsovo® ), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the treatment of adults with pretreated, advanced, mIDH1 cholangiocarcinoma (CCA). It is presumed to exert its cytostatic effects in this setting by suppressing 2-hydroxyglutarate, an oncometabolite produced by mIDH1 that impairs cellular differentiation and promotes tumorigenesis. In the multinational phase 3 ClarIDHy study in patients with pretreated, advanced mIDH1 CCA, monotherapy with ivosidenib once daily significantly prolonged progression-free survival (PFS) and almost doubled the disease control rate compared with placebo...
October 19, 2023: Targeted Oncology
Francesco Volta, Silvia La Monica, Alessandro Leonetti, Letizia Gnetti, Mara Bonelli, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti, Kamal Eltayeb, Roberta Minari, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
BACKGROUND: Cell-cycle regulators are mutated in approximately 40% of all cancer types and have already been linked to worse outcomes in non-small cell lung cancer adenocarcinomas treated with osimertinib. However, their exact role in osimertinib resistance has not been elucidated. OBJECTIVE: In this study, we aimed to evaluate how the CDK4/6-Rb axis may affect the sensitivity to osimertinib. METHODS: We genetically increased the level of CCND1 (Cyclin D1) and reduced the levels of CDKN2A (p16) in two different adenocarcinoma cell lines, PC9 and HCC827...
October 19, 2023: Targeted Oncology
Minmin Zhao, Shanhu Qiu, Xin Wu, Pengcheng Miao, Zhi Jiang, Tao Zhu, Xizhong Xu, Yanling Zhu, Bei Zhang, Donglan Yuan, Yang Zhang, Wei Sun, Aiqin He, Min Zhao, Wenjie Hou, Yingli Zhang, Zhuyan Shao, Meiqun Jia, Mei Li, Jun Chen, Jingcheng Xu, Bingwei Chen, Ying Zhou, Yang Shen
BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors are a new maintenance therapy option for patients with ovarian cancer (OC). OBJECTIVE: To evaluate the efficacy and influencing factors of the novel PARP inhibitor niraparib for maintenance treatment of Chinese patients with advanced OC. PATIENTS AND METHODS: In this retrospective multicenter real-world study patients with advanced OC from 15 hospitals throughout China were enrolled...
October 17, 2023: Targeted Oncology
Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach
Supplementary file1 (MP4 21169 KB).
October 4, 2023: Targeted Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.